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Abstract
Objective: The	2014	update	of	 the	Swiss	 law	on	 research	 increases	patients'	pro-
tection;	 it	adds	specific	 requirements	 for	emergency	situations,	 implying	an	active	
search	for	patients'	wishes	regarding	research	participation;	the	possibility	of	con-
sent waivers is not clearly stated. We explored its practical impact in a RCT on criti-
cally ill adults.
Methods: We considered prospectively collected consents of a multicenter trial ad-
dressing	the	impact	of	continuous	EEG	on	survival.	We	assessed	the	proportions	of	
consents	obtained	strictly	according	to	the	law,	of	specific	waivers	for	this	study	ob-
tained	from	the	IRB	(early	death;	relatives'	unavailability	despite	repeated	attempts),	
and the yield of retrieving statements on willingness to research participation. We 
compared the proportion of consent refusals with those of recent trials in similar 
environments,	and	estimated	the	potential	impact	on	study	results.
Results: Of	402	recruited	patients,	six	had	double	inclusions,	one	died	before	inter-
vention,	and	27	(6.7%,	alive	on	long-term)	were	excluded	following	consent	refusal	
or	withdrawal,	leaving	368	analyzable	patients.	Specific	waivers	allowed	inclusion	of	
134	(36.4%)	patients,	while	informed	consents	were	obtained	for	all	others.	A	state-
ment	of	willingness	to	research	participation	was	found	in	only	14.1%.	In	recent	trials,	
consent	refusal	oscillated	between	0%–23%,	according	to	different	waiver	policies.
Conclusions: Consent waivers should be specifically foreseen to prevent losing a 
potentially	 relevant	 proportion	of	 patients	 reaching	 endpoints,	 and	 ensure	 results	
generalizability.	The	yield	of	looking	for	willingness	to	research	participation	seems	
low; this questions its current usefulness and calls for a public awareness campaign.
K E Y W O R D S
Declaration	of	Helsinki,	electroencephalography,	Ethic	Commission,	IRB,	Switzerland
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1  | INTRODUC TION
Obtaining	informed	consent	represents	one	of	the	main	principles	of	
clinical	research	enacted	by	the	Declaration	of	Helsinki	(World	Medical	
Association,	2013),	Good	Clinical	Practice	(ICH	Harmonised	Tripartite	
Guideline	E2016	(2016),	2016),	and	by	the	country's	law	(in	Switzerland:	
Federal	Act	on	Research	involving	Human	Beings,	2011a).	Clinical	re-
search on critically ill patients or in emergency situations is essential to 
attempt	decreasing	the	related	morbidity	and	mortality,	but	this	popu-
lation cannot be easily involved; specific regulations exist in these set-
tings	(Federal	Act	on	Research	involving	Human	Beings,	2011b,	2011c).
In	Switzerland,	 the	 law	regulating	research	was	updated	 in	2014	
(Federal	Act	on	Research	involving	Human	Beings,	2011a).	In	research	
with	no	direct	expected	benefit,	the	project	must	imply	“minimal	risks,”	
agreed	upon	by	the	Ethic	Commission	(EC).	Moreover,	while	the	pos-
sibility to obtain specific consent waivers is not explicitly described 
(EC	may	nevertheless	grant	 these,	 in	practice),	a	patient's	statement	
regarding willingness or opposition to participate to clinical research 
(made before the lack of capacity) has to be actively sought by inves-
tigators,	provided	there	are	no	“signs	and	symptoms”	showing	the	pa-
tient's	unwillingness	to	participate	(Federal	Act	on	Research	involving	
Human	Beings,	2011b).	This	wording	appears	rather	unspecific,	espe-
cially	 for	critically	 ill	patients.	 Ideally,	a	written	note	should	be	 iden-
tified;	 alternatively,	 the	 legal	 representative	 may	 refer	 a	 “clear	 oral	
statement”	by	the	patient	(i.e.,	the	opinion	of	the	legal	representative	is	
not	relevant).	It	is	questionable	if	the	general	population	may	routinely	
think	at	providing	such	a	statement,	and	if	a	legal	representative	may	
always	discriminate	between	the	own	opinion	and	that	of	the	patient.	If	
no	patient's	opposition	is	found,	investigators	in	emergency	situations	
should obtain at inclusion a statement by an independent physician 
with	 the	 fiduciary	duty	of	safeguarding	patients'	 interests.	 Informed	
consent should be obtained as soon as possible if the patient recovers 
a	capacity	of	judgment;	otherwise,	a	proxy	consent	should	be	sought	
(Federal	Act	on	Research	involving	Human	Beings,	2011c;	Ordinance	
on	Clinical	Trials	in	Human	Research,	2013);	however,	the	timeframe	of	
a	“permanent	lack	of	judgment	capacity”	is	not	clearly	defined	and	thus	
depends on subjective appreciation.
To	our	knowledge,	application	of	the	current	Swiss	rules	regard-
ing research in emergency situations and patients unable to consent 
has not been explored; this aspect has received limited attention 
also in other settings. This work describes the process of informed 
consent in a trial involving adults with acute consciousness impair-
ment,	in	order	to	assess	whether	current	laws	can	be	translated	into	
practice,	and	identify	aspects	that	may	be	improved.
2  | METHODS
2.1 | Patients and clinical context
Nonconvulsive	 (subclinical)	 seizures	and	status	epilepticus	 (SE)	are	
frequent	 in	 comatose	 patients,	 and	 associated	 with	 considerable	
morbidity	and	mortality	(Towne	et	al.,	2000;	Zehtabchi	et	al.,	2013).	
Continuous	EEG	(cEEG)	improves	nonconvulsive	seizures	and	SE	de-
tection	compared	with	routine	EEG	(rEEG)	lasting	<30 min (Claassen 
et	 al.,	 2004)	 and	 is	 broadly	 recommended	 in	 critically	 ill	 patients	
(Claassen	 et	 al.,	 2013;	 Herman	 et	 al.,	 2015a,	 2015b).	 However,	
the	 effect	 on	 outcome	 remains	 unclear.	 CERTA	 (Continuous	 EEG	
Randomized	 Trial	 in	Adults,	NCT03129438)	 (Rossetti	 et	 al.,	 2018)	
aimed	to	determine	whether	cEEG	in	adults	with	consciousness	im-
pairment	 correlated	with	 a	 better	 outcome	 than	 rEEG.	 It	 involved	
four	 large	 Swiss	 hospitals	 (CHUV	 Lausanne;	 Hôpital	 du	 Valais;	
Inselspital	Bern;	Universitätsspital	Basel).	Between	April	2017	and	
November	2018,	adults	with	acute	consciousness	impairment	in	an	
intensive/intermediate	 care	 unit	 needing	 an	 EEG	 for	 clinical	 pur-
poses	were	pragmatically	 recruited	and	 randomized	1:1	 to	a	cEEG	
(30–48	hr)	or	2	rEEG	(20	min	each;	Rossetti	et	al.,	2020;	intervention	
not	blinded).	The	original	protocol	may	be	found	in	the	Supporting	
Information.	The	primary	endpoint	was	survival	at	six	months.	The	
study	was	approved	by	local	EC	(authorization:	2017-00268);	regula-
tory procedures were verified by an independent monitor.
2.2 | Procedures and variables
We	 retrospectively	 analyzed	 the	 consent	 procedure	 of	 recruited	
subjects,	which	 occurred	 under	 the	 current	 Swiss	 law.	Before	 en-
rollment,	 a	 statement	had	 to	be	always	 signed	by	an	 independent	
physician.	 If	 the	 patient	 recovered	 judgment	 capacity,	 a	 post	 hoc	
consent	had	to	be	sought	within	the	6-month	follow-up.	In	the	suba-
cute	period,	if	this	was	impossible	after	one	week	(±3 days; defined 
for this study as the time when judgment capacity was considered 
“permanently”	lacking,	considering	a	compromise	between	the	end	
of intervention and the need to prevent losing contact with proxy 
with	elapsing	time),	a	proxy	consent	by	a	relative	or	legal	representa-
tive	was	sought.	During	follow-up	at	4	weeks	and/or	6	months,	in-
vestigators	contacted	the	patient,	a	legal	representative,	the	treating	
physician,	or	consulted	medical	files	to	evaluate	the	patient's	state	
(without quantitative cognitive assessments) and obtain a post hoc 
consent.	If	consent	was	refused	by	proxy	or	the	patient,	all	collected	
data	 had	 to	 be	 discarded.	 Under	 predefined	 conditions,	 however,	
in view of the minimal risks related to participation to this RCT felt 
to be negligible as compared to the potential collective benefit (as-
sessing	a	biological	surveillance	but	not	a	therapeutic	intervention),	
waivers	specific	for	this	study	were	obtained	from	the	EC,	to	allow	
enrolling patients and using clinical data despite lack of informed 
consents. This applied in five situations: a—no representative could 
be	identified,	or	b—despite	identification,	no	consent	was	collected,	
despite	at	least	three	documented	attempts	to	give	information,	and	
3	others	to	collect	the	signature;	c—a	decision	of	withdrawal	of	life-
sustaining therapy was made (to prevent additional distress to the 
family); d—a patient died before proxy consent was collected (idem); 
e—an oral agreement was provided to an investigator accompanied 
by	a	caregiver	witness,	unrelated	to	the	study.
Demographical,	 administrative	 (statement	 of	 wishes,	 authori-
zation	 from	 independent	 physicians,	 informed	 consents	 obtained	
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or	 refused/	 withdrawn,	 state	 of	 capacity	 to	 consent),	 and	 clinical	
information was prospectively collected for the trial. We assessed 
the	 proportion	 of	 consents	 obtained	 in	 accordance	 with	 the	 law,	
determined the proportion obtained directly from the patient or 
from	a	proxy,	and	the	proportion	of	patients,	proxy,	or	legal	repre-
sentative	consent	refusals	or	withdrawals,	stratified	for	study	inter-
vention. We also assessed exceptions in which data were collected 
according	 to	EC-granted	waivers.	We	compared	 the	proportion	of	
consent	refusals	and	withdrawals	obtained	in	the	CERTA	study	with	
six recent large international trials involving critically ill patients 
(Cooper	et	al.,	2018;	Kapur	et	al.,	2019;	Lascarrou	et	al.,	2019;	Legriel	
et	al.,	2016;	Navarro	et	al.,	2016;	Nielsen	et	al.,	2013).	As	this	 is	a	
retrospective	analysis	of	a	prospective	trial,	and	Swiss	law	explicitly	
states that data from patients who refused participation (even post 
hoc)	should	be	destroyed,	we	were	unable	to	explore	specific	refusal	
reasons.
2.3 | Calculations
We present descriptive statistics; frequencies were tested using 
2-sided	Fisher's	exact	tests	using	STATA	version	14.
3  | RESULTS
The	 trial	 included	 402	 adults	 with	 acute	 consciousness	 disorders	
hospitalized	 in	an	 intensive/intermediate	care	unit	of	the	four	par-
ticipating	hospitals;	201	each	received	cEEG	and	rEEG.	Seven	(1.7%)	
patients	were	 excluded	 early	 (six	were	 included	 twice,	 one	 death	
prior	 to	 intervention),	 and	 data	 from	 27	 (6.7%)	 additional	 partici-
pants	were	 unavailable	 because	 of	 consent	 refusal	 (24)	 or	 lack	 of	
it	(3;	Table	1);	there	were	no	differences	across	centers.	Among	24	
consent refusals (+3	“consent	defaults”:	subjects	lacking	consent	and	
in	whom	waivers	did	not	apply),	15	(+2)	occurred	in	the	rEEG	and	9	
(+1)	in	the	cEEG	arm.	We	thus	had	368	(91.5%)	analyzable	patients.	
Four	 patients	were	 lost	 to	 follow-up,	 but	 clinical	 information	was	
available	only	until	the	4th	week	(Figure	1).
The	 main	 results	 are	 summarized	 in	 Figure	 1	 and	 Table	 1.	
Written	 authorizations	 from	 an	 independent	 physician	 were	 col-
lected	before	inclusion	in	all	368	analyzable	patients.	A	clear	state-
ment regarding willingness to research participation was found in 
52/368	(14.1%)	of	analyzable	patients,	mostly	retrieved	orally	from	
a proxy (Table 2) after repeated attempts in an emergency/critical 
situation.	Again,	 there	were	no	differences	across	 recruiting	 cen-
ters.	Of	relevance,	134	patients	(36.4%)	remained	in	the	study	and	
their	data	were	analyzed	in	the	absence	of	any	consent,	according	
to the predefined waivers (Table 1). Data following consent refusals 
or	 defaults	were	 destroyed;	 therefore,	we	were	 unable	 to	 distin-
guish	patient's	post	hoc	refusal	from	an	oral	opposition	to	partici-
pate	in	the	trial	from	relatives,	or	from	an	objection	documented	in	
the medical file.
Figure 2 illustrates the distribution of recovery of judgment ca-
pacity	along	the	study	period.	In	132	(35.9%	of	analyzable	patients),	
this	occurred	between	inclusion	and	the	6	months’	assessment,	but	
for	only	8	of	them	(5.8%	of	the	patients	who	regained	judgment	ca-
pacity),	within	the	first	4	days,	corresponding	to	the	lower	limit	for	
the	predefined	7	±	3	days	of	“permanent	lack	of	judgment	capacity.”	
We	 further	 analyzed	 the	 type	of	 the	110	waivers	 collected	 in	 the	
CHUV	(details	on	the	waivers	in	other	hospitals	were	not	available;	
Figure 3): consent was lacking mostly because of care withdrawal or 
early	death.	In	five	cases	(4.5%),	the	form	was	missing,	but	a	docu-
mented,	witnessed	oral	consent	was	obtained.
Proportions of consent refusals or withdrawals in recent studies 
involving	critically	 ill	patients	vary	 from	0%	to	23.2%	 (Table	3),	al-
though detailed information is at times lacking in the papers.
CHUV (318 
patients)
Other Swiss sites 
(84 patients)
p 
(Fisher)
Patients excluded because double 
inclusions or death before intervention
6	(1.9%) 1	(1.2%) 1.000
Patient's	data	analyzable 289	(92.6%) 79	(95.2%) .624
Patient's	post	hoc	consent 61	(19.6%) 16	(19.3%)
Proxy consent 78	(25.0%) 24	(28.9%)
Proxy	followed	by	patient's	post	hoc	
consent
40	(12.8%) 15	(18.1%)
Waiver	according	to	the	EC 110	(35.3%) 24	(28.9%) .480
Patient's	data	not	analyzable 23	(7.4%) 4	(4.8%) .624
Patient's	post	hoc	consent	refusal 12	(3.8%) 1	(1.2%)
Proxy consent refusal 8	(2.6%) 3	(3.2%)
Patient's	consent	default 1	(0.3%) 0
Proxy consent default 2	(0.6%) 0 .576
Note: Consent default means not receiving the consent form from a patient or proxy (who did not 
decline	participation),	and	impossibility	to	apply	a	waiver	as	defined	by	the	EC.
Abbreviation:	EC,	Ethics	Commission.
TA B L E  1   Distribution of the data 
among the different sites (column 
percentages);	7	patients	that	were	
excluded early are not reported
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F I G U R E  1  Study	participants'	flow	diagram
CHUV (289 
patients)
Other Swiss centers (79 
patients)
p 
(Fisher)
Total per site 38	(13.1%) 14	(17.7%) 0.361
Source
Relative or legal 
representative
36	(12.5%) 14	(17.7%)
Patient's	medical	file 2	(0.7%) 0 1.000
TA B L E  2  Source	of	statement	of	
wishes	among	analyzable	patients	(column	
percentages)
F I G U R E  2   Capacity of consent 
recovery through the different 
assessment time points. The number 
of patients regaining their capacity of 
consent during the mentioned period is 
illustrated	in	dark	gray,	and	the	number	
of patients who already recovered their 
judgment is in light gray. The whole 
column represents the total of patients 
able	to	consent	at	the	respective	time-
point
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4  | DISCUSSION
While research on critically ill patients is needed to improve their 
prognosis	 (Luce	et	al.,	2004),	 it	 is	generally	difficult	 to	 involve	this	
vulnerable	population	in	research.	This	assessment	of	a	randomized	
trial on adults with acute consciousness impairment shows that data 
were	available	for	analysis	in	accordance	with	the	EC	requirements	
in	more	 than	 90%	 of	 enrolled	 patients.	 However,	 ad	 hoc	waivers	
granted	 by	 the	 EC	 allowed	 analysis	 of	 more	 than	 1/3	 of	 patients	
lacking	informed	consent.	It	was	possible	to	identify	a	statement	of	
wishes reporting willingness to participate to clinical research in less 
than	1/7	of	patients	(almost	never	in	patients’	charts).	Finally,	con-
sent	was	refused	or	withdrawn	in	nearly	7%	of	enrollments,	and	data	
had to be discarded.
The time beyond which lack of consent capacity was considered 
as	 permanent	 was	 preset	 at	 7	 (±3)	 days	 (EEG	 interventions	 were	
finished on the 3rd day: proxy consents concerned then the use 
of	patients’	data	and	not	authorization	to	perform	EEG).	It	 is	 inter-
esting	to	observe	that	 indeed	almost	95%	of	 the	subjects	who	re-
gained	their	judgment	capacity	recovered	it	at	4	days	or	later,	which	
retrospectively	 corroborates	 this	 time	 point.	 During	 follow-up,	
investigators	 repeatedly	 tried	 to	define	 the	patient's	 judgment	ca-
pacity and to obtain post hoc consents: several attempts had to be 
carried	out	per-protocol,	but,	unfortunately,	no	details	on	this	pro-
cedure were collected.
Initial	 steps	 complied	 with	 the	 current	 Swiss	 regulatory	 re-
quirements:	 for	 each	 analyzable	 patient,	 we	 obtained	 consent	
from	 independent	 physicians.	 Informed	 consents	were	 obtained	
in	 approximately	 2/3	 of	 analyzable	 patients,	 more	 frequently	
by proxy; this occurred despite the possible stress related to 
emergency	 or	 critical-care	 conditions	 (Azoulay	 et	 al.,	 2005).	
International	and	Swiss	laws	stipulate	informed	consent	as	a	pre-
requisite	for	research	(Federal	Act	on	Research	involving	Human	
Beings,	2011a;	ICH	Harmonised	Tripartite	Guideline	E2016	(2016),	
2016;	World	Medical	Association,	2013).	However,	 in	 this	study,	
EC	 allowed	waivers	 in	 particular	 situations,	 and	 finally	 informed	
consent	 was	 waived	 in	 36%	 of	 analyzable	 patients,	 mostly	 be-
cause	of	 intensive	care	withdrawal	or	early	death.	Of	 relevance,	
strictly	applying	the	Swiss	law,	most	of	these	patients	would	have	
been excluded from analysis. This large percentage underlines the 
F I G U R E  3  Proportions	of	the	different	types	of	waivers	in	the	absence	of	informed	consent	CHUV
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paramount importance to carefully define these conditions during 
redaction	 of	 the	 study	 protocol:	without	 a	 dedicated	 authoriza-
tion	to	use	these	data,	a	considerable	patient	proportion	(mostly	
reaching	the	study	primary	outcome,	namely	death)	would	be	lost	
in	such	a	trial,	generating	a	potentially	relevant	 inclusion	bias	af-
fecting	the	results.	In	a	British	study,	only	certain	hospitals	were	
allowed to waive proxy consent in emergency situations: waiving 
consents	 shortened	 the	average	 time	 to	 randomization	 from	4.4	
to	3.2	hr,	and	increased	the	average	number	of	participants	from	
1.5	to	2	per	month	(Roberts,	2004).	Two	other	studies	are	consis-
tent	with	this	observation,	showing	that	waiving	consents	allows	
enrolling	more	patients	(Annane	et	al.,	2004;	Clifton	et	al.,	2002).	
Additionally,	a	Dutch	study	in	an	intensive-care	setting	found	that	
an intervention effect can be significantly lost after excluding pa-
tients	lacking	deferred	consent	(i.e.,	consent	obtained	after	enroll-
ment,	by	patients	or	proxy)	(Jansen	et	al.,	2010).
Current	Swiss	law	may	also	prove	problematic,	in	this	clinical	en-
vironment,	regarding	identification	of	a	clear	statement	of	wishes	re-
porting willingness to participate in a clinical trial. This was identified 
in	approximately	14%	of	enrolled	patients,	nearly	exclusively	related	
by	proxy,	despite	repetitive	attempts.	Our	proportion	seems	broadly	
in	line	with	that	reported	recently	in	a	Swiss	emergency	department	
(20%)	(Slankamenac	et	al.,	2020).	Unfortunately,	the	number	and	de-
tails of statement of wishes opposing research were not available 
in	our	study,	since	this	was	an	exclusion	criterion	and	was	not	pro-
tocolled.	In	practice,	very	often	relatives	did	not	know	the	patient's	
opinion	upon	clinical	research,	and	the	information	was	almost	never	
available in medical files. These observations raise the question 
about	the	relevance	of	repeated	efforts	to	look	for	these	wishes,	to	
be balanced against potential benefits of the implementation of an 
awareness campaign on research (similar to organ transplantation). 
Further,	“signs	and	symptoms	showing	patient's	opposition”	repre-
sent in our view vague concepts not applicable in practice.
While	 the	 proportion	 of	 6.7%	 excluded	 due	 to	 consent	 issues	
seems	relatively	small	at	first	glance,	it	may	exert	an	effect	in	terms	
of study results: as refusals occurred only in survivors (data of pa-
tients	dying	early	was	managed	through	waivers),	mortality	increased	
in	the	analyzed	sample.	Moreover,	since	no	analysis	of	these	patients	
TA B L E  3   Proportion of consent refusals and withdrawals in various studies
Study Country Informed consent process
Study 
participants
Consent refusals or 
withdrawals
CERTA	(Rossetti	et	al.,	2020) Switzerland Enrollment	without	informed	
consent,	authorization	from	an	
independent	physician,	proxy	
written informed consent and 
subsequently from the patient if 
he/she regained capacity.
402 27	(6.7%)
TTM	for	Cardiac	Arrest	with	
Nonshockable	Rhythm	(Lascarrou	
et	al.,	2019)
France Participation without informed 
consent	(standard	of	care),	
information to relatives only.
548 3	(0.5%)
TTM	at	33°C	versus	36°C	
after	Cardiac	Arrest	(Nielsen	
et	al.,	2013)
Europe	and	Australia Enrollment	without	informed	
consent obtained in a second time 
from the patient or surrogate in 
writing or orally.
950 4	(0.4%)a 
SAMUKeppra	(Navarro	
et	al.,	2016)
France Enrollment	with	proxy	consent	or	
if	not	available,	with	authorization	
from the emergency physician 
before	the	enrollment.	Patient's	
post hoc written consent in a 
second time.
203 47	(23.2%)
Hypothermia	for	Neuroprotection	
in	Convulsive	Status	Epilepticus	
(Legriel	et	al.,	2016)
France Proxy	consent	or	if	not	available,	
authorization	from	the	emergency	
physician before the enrollment. 
Patient's	post	hoc	written	consent	
as soon as possible.
270 2	(0.7%)
Randomized	Trial	of	Three	
Anticonvulsant	Medications	
for	Status	Epilepticus	(Kapur	
et	al.,	2019)
USA Enrollment	without	informed	
consent obtained in a second time 
from relatives in writing.
400 0%	(none	noted!)
POLAR	(Cooper	et	al.,	2018) Australia,	New	Zealand,	
France,	Switzerland,	Saudi	
Arabia,	and	Qatar
Enrollment	without	informed	
consent,	proxy	written	informed	
consent and subsequently from 
the patient if he/she regained 
capacity.
511 11	(2.6%)
a160/1100	(14%)	patients	not	enrolled,	as	they	lacked	informed	consent.	
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was	allowed,	we	cannot	assure	that	they	did	not	represent	a	different	
subgroup	in	terms	of	demographics	or	etiologies,	nor	assess	the	rea-
sons	for	refusal.	It	seems	reasonable	to	consider	this	aspect	in	future	
studies in similar settings and allow at least partial use of data from 
these	patients,	 in	order	to	ensure	results’	generalizability.	 In	fact,	a	
recent Canadian study involving critically ill patients showed that 
those	with	consent	refusals	were	the	most	severely	 ill	 (Tropolovec-
Vranic	et	al.,	2014),	while	in	our	study	only	alive	patients	could	refuse.	
Rates of refusals or withdrawals appear much lower when formal 
consent is not required due to general waivers in emergency situa-
tions	(Kapur	et	al.,	2019),	where	often	the	only	requirement	is	to	in-
form the relatives on the opportunity for the patient to oppose the 
use	of	data	(0.5%;	Kapur	et	al.,	2019;	Lascarrou	et	al.,	2019),	or	when	
informed	consent	can	be	obtained	orally	(1.2%;	Nielsen	et	al.,	2013).	
Conversely,	refusals	seemed	higher	(23.2%)	in	a	recent	French	trial	on	
convulsive	SE,	in	which	proxy	consent	was	required	(or,	if	unavailable,	
an	authorization	from	a	physician;	Navarro	et	al.,	2016).	Globally,	in	
recent	studies,	the	variability	of	consent	refusals	appears	wide	and	is	
probably related to different regulations and study designs.
A	recent	US	assessment	focusing	on	emergency	conditions	iden-
tified 28 studies using consent waivers over the last 2 decades; only 
46%	of	them	detailed	on	its	 justification	(Klein	et	al.,	2018).	 In	the	
United	States,	the	Department	of	Health	and	Human	Services	issued	
a	Common	Rule	in	1996,	subsequently	updated,	where	recruitment	
of patients is not able to consent is foreseen in emergency situa-
tions	 (https://www.fda.gov/files/	about	%20fda/	publi	shed/Excep	
tion-from-Infor	med-Conse	nt-Requi	remen	ts-for-Emerg	ency-Resea	
rch.pdf;	Bauer	&	Tate,	2020).	FDA	regulations	foresee	consent	waiv-
ers for the emergency use of a test article in determined situations 
(21CFR 50 and 21CFR56); they also provide for waiver of informed 
consent for planned emergency research under 21CFR50 (https://
www.acces	sdata.fda.gov/scrip	ts/cdrh/cfdoc	s/cfcfr/	CFRSe	arch.
cfm?CFRPa rt=50).	This	has	to	occur	under	EC	supervision,	and	par-
ticipants	should	have	life-threatening	conditions,	impaired	decisional	
capacity	with	no	time	to	obtain	surrogate	consent,	and	the	research	
intervention	should	offer	a	chance	of	benefit.	Furthermore,	the	in-
vestigator	should	define	a	time-window	to	look	for	a	proxy	or	legal	
representative.	The	latter	point	seems	similar	to	the	Swiss	law,	but	
the	window	is	potentially	longer	in	Switzerland	(up	to	6	months	in	our	
study: consent has to be sought as long as a patient is in the study). 
Additionally,	 the	need	to	actively	 look	for	a	previous	statement	of	
wishes and the lack of explicit phrasing regarding possible consent 
waivers	in	emergency	situations	seems	peculiar	for	Switzerland.
Although	we	 analyzed	 a	 prospectively	 collected	 set	 of	 data,	
the lack of information regarding patients in whom consent was 
refused	represents	a	major	limitation.	Additionally,	our	retrospec-
tive	analysis	prevented	addressing	further	aspects,	such	as	quan-
tifying	the	time	spent	for	obtaining	consents.	The	sample	size	was	
not specifically powered for this analysis (but tailored for identi-
fication	of	mortality	differences	across	EEG	intervention	groups).	
Consent	 capacity	 was	 not	 evaluated	 quantitatively.	 Finally,	 this	
study	 is	 not	 automatically	 applicable	 to	 a	 pediatric	 population,	
where	 regulatory	 requirements	 may	 differ	 significantly,	 and	 in	
places	outside	Switzerland.	We	however	believe	that	since	Swiss	
regulations	 closely	 follow	 the	 Declaration	 of	 Helsinki	 (World	
Medical	 Association,	 2013)	 and	 Good	 Clinical	 Practice	 (ICH	
Harmonised	Tripartite	Guideline	E2016	(2016),	2016),	it	is	reason-
able	to	assume	generalizability	of	our	findings.
5  | CONCLUSION
In	our	RCT,	data	from	7%	of	recruited	subjects	had	to	be	discarded	
due to lack of informed consent; this influenced the primary end-
point	(mortality).	Furthermore,	more	than	1/3	of	recruited	subjects,	
mostly	dying	early,	 could	be	 included	and	analyzed	only	 following	
specific	waivers	 accorded	by	 the	EC.	This	 underscores	 the	 impor-
tance	of	such	waivers,	especially	in	a	clinical	context	where	risk	of	
participation	is	judged	low,	and	to	address	reasons	of	drop-out	due	
to	lack	of	consents,	in	order	to	ensure	generalizability	of	results.	In	
this	particular	environment,	looking	for	patients’	statements	on	will-
ingness	to	participate	to	research	seems	to	have	a	low	yield,	with-
out	dedicated	public	campaigns.	Finally,	we	highlight	the	efforts	to	
achieve high ethical standards in research with participants unable 
to	consent	in	emergency	setting.	Such	efforts	should	be	considered	
when	assessing	the	value	of	studies,	beyond	statistical	results,	par-
ticularly when comparing works from different consent strategies 
and settings.
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